Samsung Bioepis has entered a new global agreement with Sandoz to develop and commercialise up to five next‑generation ...

Atrogi has dosed the first participants in a human study of its lead candidate ATR‑258, marking a significant step forward for the Stockholm-based biotech as it advances its next‑generation approach ...

R1 Therapeutics has launched with an oversubscribed $77.5 million Series A financing and an exclusive global licence to ...

Almirall has reported positive top-line results from its phase 3 ADorable-1 trial, which evaluated lebrikizumab in children ...

Terumo Blood and Cell Technologies has entered a new collaboration with Taiwan Bio Therapeutics to transition regulatory T‑cell manufacturing onto the automated Quantum Flex platform, marking a shift ...

Elevara Medicines has dosed the first patient in its phase 2b START-SYNERGY trial, marking a key step in the development of ELV001, an oral CDK4/6 inhibitor being studied for rheumatoid arthritis in ...

Incyte has received European Commission approval for Zynyz (retifanlimab) in combination with carboplatin and paclitaxel as a ...

The MHRA has approved deuruxolitinib, marketed as Leqselvi, for the treatment of severe alopecia areata in adults, offering a new therapeutic option for people living with the autoimmune condition.

Chief Executive Officer Sean A MacDonald added: “The successful completion of this Phase I study represents an important step for Kainova Therapeutics, highlighting the strength of our innovative ...

UCB has announced positive topline results from its BE BOLD trial, the first head‑to‑head study in active psoriatic arthritis to demonstrate superiority of one licensed biologic therapy over an IL‑23 ...

Astellas Pharma has announced that the National Institute for Health and Care Excellence has issued Final Draft Guidance recommending fezolinetant 45 mg once daily for treating moderate to severe ...

The Briefing Room – what next for healthcare communications?